Preclinical Experimental and Mathematical Approaches for Assessing Effective Doses of Inhaled Drugs, Using Mometasone to Support Human Dose Predictions

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 29, Issue 4, 2016, Pages 362-377

  Caniga, Michael ^a   Cabal, Antonio ^a   Mehta, Khamir ^a   Ross, David S ^c   Gil, Malgorzata A ^a   Woodhouse, Janice D ^a   Eckman, Joseph ^a   Naber, John R ^a   Callahan, Marissa K ^a   Goncalves, Luciano ^a   Hill, Susan E ^a   Mcleod, Robbie L ^a   McIntosh, Fraser ^b   Freke, Mark C ^b   Visser, Sandra A G ^a   Johnson, Neil ^a   Salmon, Michael ^a   Cicmil, Milenko ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c ROCHESTER INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

drug dissolution and distribution; inhaled corticosteroid; inhaled delivery; inhaled drug development; PK PD modeling

Indexed keywords

LIPOPOLYSACCHARIDE; MOMETASONE FUROATE; AEROSOL; ANTIINFLAMMATORY AGENT;

ALTERNARIA ALTERNATA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SOLUBILITY; DRUG TRANSPORT; EFFECTIVE DOSE (PHARMACOLOGY); IN VIVO STUDY; LIPOPHILICITY; LUNG FLUID; MALE; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PNEUMONIA; PREDICTION; RAT; AEROSOL; ALTERNARIA; ALTERNARIOSIS; ANIMAL; BIOLOGICAL MODEL; BROWN NORWAY RAT; CHEMICALLY INDUCED; DISEASE MODEL; DOSE CALCULATION; DRUG EFFECTS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG DISEASES, FUNGAL; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; ALTERNARIA; ALTERNARIOSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DRUG DOSAGE CALCULATIONS; HUMANS; LIPOPOLYSACCHARIDES; LUNG; LUNG DISEASES, FUNGAL; MALE; MODELS, BIOLOGICAL; MOMETASONE FUROATE; PNEUMONIA; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84979697133     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2015.1253     Document Type: Article

References (38)

1. Bousquet J, and Khaltaev N, eds: Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. World Health Organization. 2007.
2. Diaz-Guzman E, and Mannino DM: Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:7-16.
3. Mullane K: The increasing challenge of discovering asthma drugs. Biochem Pharmacol. 2011;82:586-599.
4. Cooper AE, Ferguson D, and Grime K: Optimisation of DMPK by the inhaled route: Challenges and approaches. Curr Drug Metab. 2012;13:457-473.
5. Klein NC, Go CH, and Cunha BA: Infections associated with steroid use. Infect Dis Clin North Am. 2001;15:423-432.
6. Toogood JH: Efficiency of inhaled versus oral steroid treatment of chronic asthma. N Engl Reg Allergy Proc. 1987; 8:98-103.
7. Lipworth BJ, and Jackson CM: Effects of oral and inhaled corticosteroids on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1999;104:713-714.
8. Dahl R, Chuchalin A, Gor D, Yoxall S, and Sharma R: EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med. 2006;100: 1152-1162.
9. Frampton JE: Mometasone/formoterol inhalation aerosol: In asthma uncontrolled on medium-or high-dose inhaled corticosteroids. Drugs. 2012;72:1229-1241.
10. Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustavsson L, Hardy C, Hassall D, Jones R, Lock R, Maas J, McGovern T, Pitcairn GR, Somers G, and Wolff RK: Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev. 2011;63:69-87.
11. Cheng YS: Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS Pharm Sci Tech. 2014; 15:630-640.
12. Weber B, and Hochhaus G: A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J. 2013;15:159-171.
13. Yu J, and Rosania GR: Cell-based multiscale computational modeling of small molecule absorption and retention in the lungs. Pharmaceut Res. 2010;27:457-467.
14. Yu J, Zheng N, Mane G, Kyoung AM, Hinestroza JP, Zhu H, Stringer KA, and Rosania GR: A cell-based computational modeling approach for developing site-directed molecular probes, PLoS Comput Biol. 2012;8:e1002378.
15. Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, Hochhaus G, and Tattersfield AE: Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol. 2006; 62:412-419.
16. Gil MA, Caniga M, Woodhouse JD, Eckman J, Lee H-H, Salmon M, Naber J, Hamilton VT, Sevilla RS, Bettano K, Klappenbach J, Moy L, Correll CC, Gervais FG, Siliphaivanh P, Zhang W, Zhang-Hoover J, McLeod RL, and Cicmil M: Anti-inflammatory actions of CRTH2 and glucocorticoid receptor antagonism in a novel rat model of Alternaria alternata elicited pulmonary inflammation. Eur J Pharmacol. 2014;743C:106-116.
17. Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, Karantabias G, Johnson N, Karlsson A, Kilgour JD, and McDonald P: Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in nonclinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20:1179-1189.
18. Berger R, and Berger WE: Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler. Allergy Asthma Proc. 2013;34:52-58.
19. Hintz RJ, and Johnson CS: The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharmaceut. 1989;51:9-17.
20. Noyes AA, and Whitney WR: The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897; 19:930-934.
21. Hochhaus G: Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: Potential effects on clinical safety and efficacy. Clin Ther. 2008;30:1-13.
22. Davies B, and Morris T: Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-1095.
23. Affrime MB, Cuss F, Padhi D, Wirth M, Pai S, Clement RP, Lim J, Kantesaria B, Alton K, and Cayen MN: Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000;40:1227-1236.
24. Scheuch G, Kohlhaeufl MJ, Brand P, and Siekmeier R: Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev. 2006;58:996-1008.
25. Barton BE, Jakway JP, Smith SR, and Siegel MI: Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol. 1991;13:251-261.
26. Derendorf H, Nave R, Drollmann A, Cerasoli F, and Wurst W: Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28: 1042-1050.
27. Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T, Wolfe J, Vanderwalker ML, Nolop KB, and Harrison JE: Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol. 2001;86:203-210.
28. Nayak AS, Banov C, Corren J, Feinstein BK, Floreani A, Friedman BF, Goldsobel A, Gottschlich GM, Hannaway PJ, Lampl KL, Lapidus RJ, Lawrence M, Lumry W, Munk Z, Pearlman D, Scardella AT, Schenkel EJ, Segal AT, Segall N, Silverman B, Shneyer L, Nolop KB, and Harrison JE: Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000;84:417-424.
29. Noonan M, Karpel JP, Bensch GW, Ramsdell JW, Webb DR, and Nolop KB, Lutsky BN: Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol. 2001;86:36-43.
30. Chapman RW, Curran AK, House A, Richard J, Salisbury B, Hunter JC, Anthes JC, and Phillips JE: Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats. Pulm Pharmacol Ther. 2011;24: 67-73.
31. van Helden HP, Kuijpers WC, Steenvoorden D, Go C, Bruijnzeel PL, van Eijk M, and Haagsman HP: Intratracheal aerosolization of endotoxin (LPS) in the rat: A comprehensive animal model to study adult (acute) respiratory distress syndrome. Exp Lung Res. 1997;23:297-316.
32. Doherty TA, Khorram N, Sugimoto K, Sheppard D, Rosenthal P, Cho JY, Pham A, Miller M, Croft M, and Broide DH: Alternaria induces STAT6-dependent acute airway eosinophilia and epithelial FIZZ1 expression that promotes airway fibrosis and epithelial thickness. J Immunol. 2012; 188:2622-2629.
33. Doherty TA, Khorram N, Chang JE, Kim HK, Rosenthal P, Croft M, and Broide DH: STAT6 regulates natural helper cell proliferation during lung inflammation initiated by Alternaria. Am J Physiol Lung Cell Mol Physiol. 2012;303:L577-588.
34. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, and Kita H: IL-33-responsive lineage-CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012;188:1503-1513.
35. Jansson AH, Eriksson C, and Wang X: Effects of budesonide and N-acetylcysteine on acute lung hyperinflation, inflammation and injury in rats. Vascul Pharmacol. 2005;43:101-111.
36. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, and Ranshaw LE, Knowles RG: In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2011;337:137-144.
37. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Eirefelt S, Ekelund K, Gustavsson L, and Heglund-Myrbäk T: Pulmonary drug metabolism, clearance, and absorption. In: Smyth HDC, Hickey AJ, (eds.) Controlled Pulmonary Drug Delivery. Springer, New York; 2-11; pp. 21-50.
38. Wu K, Blomgren AL, Ekholm K, Weber B, Edsbaecker S, and Hochhaus G: Budesonide and ciclesonide: Effect of tissue binding on pulmonary receptor binding. Drug Metab Dispos. 2009;37:1421-1426.